Global Anti-VEGF Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Anti-VEGF Drug market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Anti-VEGF Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Anti-VEGF Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-VEGF Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-VEGF Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-VEGF Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-VEGF Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-VEGF Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Amgen Inc, Pfizer, Inc, Xbrane Biopharma AB and Allergan, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Anti-VEGF Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Anti-VEGF Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anti-VEGF Drug, with price, sales, revenue and global market share of Anti-VEGF Drug from 2018 to 2023.
Chapter 3, the Anti-VEGF Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-VEGF Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Anti-VEGF Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGF Drug.
Chapter 14 and 15, to describe Anti-VEGF Drug sales channel, distributors, customers, research findings and conclusion.
This report is a detailed and comprehensive analysis for global Anti-VEGF Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Anti-VEGF Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-VEGF Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-VEGF Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Anti-VEGF Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anti-VEGF Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anti-VEGF Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Amgen Inc, Pfizer, Inc, Xbrane Biopharma AB and Allergan, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Anti-VEGF Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Avastin
- Lucentis
- Eylea
- Age-related Macular Degeneration
- Macular Edema Following Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy
- F. Hoffmann-La Roche Ltd
- Amgen Inc
- Pfizer, Inc
- Xbrane Biopharma AB
- Allergan
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- Viatris Inc
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Anti-VEGF Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anti-VEGF Drug, with price, sales, revenue and global market share of Anti-VEGF Drug from 2018 to 2023.
Chapter 3, the Anti-VEGF Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-VEGF Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Anti-VEGF Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anti-VEGF Drug.
Chapter 14 and 15, to describe Anti-VEGF Drug sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Anti-VEGF Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-VEGF Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Avastin
1.3.3 Lucentis
1.3.4 Eylea
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-VEGF Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Age-related Macular Degeneration
1.4.3 Macular Edema Following Retinal Vein Occlusion
1.4.4 Diabetic Macular Edema
1.4.5 Diabetic Retinopathy
1.5 Global Anti-VEGF Drug Market Size & Forecast
1.5.1 Global Anti-VEGF Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Anti-VEGF Drug Sales Quantity (2018-2029)
1.5.3 Global Anti-VEGF Drug Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 F. Hoffmann-La Roche Ltd
2.1.1 F. Hoffmann-La Roche Ltd Details
2.1.2 F. Hoffmann-La Roche Ltd Major Business
2.1.3 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product and Services
2.1.4 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.2 Amgen Inc
2.2.1 Amgen Inc Details
2.2.2 Amgen Inc Major Business
2.2.3 Amgen Inc Anti-VEGF Drug Product and Services
2.2.4 Amgen Inc Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Inc Recent Developments/Updates
2.3 Pfizer, Inc
2.3.1 Pfizer, Inc Details
2.3.2 Pfizer, Inc Major Business
2.3.3 Pfizer, Inc Anti-VEGF Drug Product and Services
2.3.4 Pfizer, Inc Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer, Inc Recent Developments/Updates
2.4 Xbrane Biopharma AB
2.4.1 Xbrane Biopharma AB Details
2.4.2 Xbrane Biopharma AB Major Business
2.4.3 Xbrane Biopharma AB Anti-VEGF Drug Product and Services
2.4.4 Xbrane Biopharma AB Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Xbrane Biopharma AB Recent Developments/Updates
2.5 Allergan
2.5.1 Allergan Details
2.5.2 Allergan Major Business
2.5.3 Allergan Anti-VEGF Drug Product and Services
2.5.4 Allergan Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Allergan Recent Developments/Updates
2.6 Bayer AG
2.6.1 Bayer AG Details
2.6.2 Bayer AG Major Business
2.6.3 Bayer AG Anti-VEGF Drug Product and Services
2.6.4 Bayer AG Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Bayer AG Recent Developments/Updates
2.7 Regeneron Pharmaceuticals Inc.
2.7.1 Regeneron Pharmaceuticals Inc. Details
2.7.2 Regeneron Pharmaceuticals Inc. Major Business
2.7.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product and Services
2.7.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
2.8 Viatris Inc
2.8.1 Viatris Inc Details
2.8.2 Viatris Inc Major Business
2.8.3 Viatris Inc Anti-VEGF Drug Product and Services
2.8.4 Viatris Inc Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Viatris Inc Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ANTI-VEGF DRUG BY MANUFACTURER
3.1 Global Anti-VEGF Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Anti-VEGF Drug Revenue by Manufacturer (2018-2023)
3.3 Global Anti-VEGF Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Anti-VEGF Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Anti-VEGF Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Anti-VEGF Drug Manufacturer Market Share in 2022
3.5 Anti-VEGF Drug Market: Overall Company Footprint Analysis
3.5.1 Anti-VEGF Drug Market: Region Footprint
3.5.2 Anti-VEGF Drug Market: Company Product Type Footprint
3.5.3 Anti-VEGF Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Anti-VEGF Drug Market Size by Region
4.1.1 Global Anti-VEGF Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Anti-VEGF Drug Consumption Value by Region (2018-2029)
4.1.3 Global Anti-VEGF Drug Average Price by Region (2018-2029)
4.2 North America Anti-VEGF Drug Consumption Value (2018-2029)
4.3 Europe Anti-VEGF Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Anti-VEGF Drug Consumption Value (2018-2029)
4.5 South America Anti-VEGF Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Anti-VEGF Drug Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Anti-VEGF Drug Sales Quantity by Type (2018-2029)
5.2 Global Anti-VEGF Drug Consumption Value by Type (2018-2029)
5.3 Global Anti-VEGF Drug Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Anti-VEGF Drug Sales Quantity by Application (2018-2029)
6.2 Global Anti-VEGF Drug Consumption Value by Application (2018-2029)
6.3 Global Anti-VEGF Drug Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Anti-VEGF Drug Sales Quantity by Type (2018-2029)
7.2 North America Anti-VEGF Drug Sales Quantity by Application (2018-2029)
7.3 North America Anti-VEGF Drug Market Size by Country
7.3.1 North America Anti-VEGF Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Anti-VEGF Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Anti-VEGF Drug Sales Quantity by Type (2018-2029)
8.2 Europe Anti-VEGF Drug Sales Quantity by Application (2018-2029)
8.3 Europe Anti-VEGF Drug Market Size by Country
8.3.1 Europe Anti-VEGF Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Anti-VEGF Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Anti-VEGF Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Anti-VEGF Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Anti-VEGF Drug Market Size by Region
9.3.1 Asia-Pacific Anti-VEGF Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Anti-VEGF Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Anti-VEGF Drug Sales Quantity by Type (2018-2029)
10.2 South America Anti-VEGF Drug Sales Quantity by Application (2018-2029)
10.3 South America Anti-VEGF Drug Market Size by Country
10.3.1 South America Anti-VEGF Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Anti-VEGF Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Anti-VEGF Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Anti-VEGF Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Anti-VEGF Drug Market Size by Country
11.3.1 Middle East & Africa Anti-VEGF Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Anti-VEGF Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Anti-VEGF Drug Market Drivers
12.2 Anti-VEGF Drug Market Restraints
12.3 Anti-VEGF Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Anti-VEGF Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-VEGF Drug
13.3 Anti-VEGF Drug Production Process
13.4 Anti-VEGF Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-VEGF Drug Typical Distributors
14.3 Anti-VEGF Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Anti-VEGF Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Anti-VEGF Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Avastin
1.3.3 Lucentis
1.3.4 Eylea
1.4 Market Analysis by Application
1.4.1 Overview: Global Anti-VEGF Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Age-related Macular Degeneration
1.4.3 Macular Edema Following Retinal Vein Occlusion
1.4.4 Diabetic Macular Edema
1.4.5 Diabetic Retinopathy
1.5 Global Anti-VEGF Drug Market Size & Forecast
1.5.1 Global Anti-VEGF Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Anti-VEGF Drug Sales Quantity (2018-2029)
1.5.3 Global Anti-VEGF Drug Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 F. Hoffmann-La Roche Ltd
2.1.1 F. Hoffmann-La Roche Ltd Details
2.1.2 F. Hoffmann-La Roche Ltd Major Business
2.1.3 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product and Services
2.1.4 F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
2.2 Amgen Inc
2.2.1 Amgen Inc Details
2.2.2 Amgen Inc Major Business
2.2.3 Amgen Inc Anti-VEGF Drug Product and Services
2.2.4 Amgen Inc Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Amgen Inc Recent Developments/Updates
2.3 Pfizer, Inc
2.3.1 Pfizer, Inc Details
2.3.2 Pfizer, Inc Major Business
2.3.3 Pfizer, Inc Anti-VEGF Drug Product and Services
2.3.4 Pfizer, Inc Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer, Inc Recent Developments/Updates
2.4 Xbrane Biopharma AB
2.4.1 Xbrane Biopharma AB Details
2.4.2 Xbrane Biopharma AB Major Business
2.4.3 Xbrane Biopharma AB Anti-VEGF Drug Product and Services
2.4.4 Xbrane Biopharma AB Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Xbrane Biopharma AB Recent Developments/Updates
2.5 Allergan
2.5.1 Allergan Details
2.5.2 Allergan Major Business
2.5.3 Allergan Anti-VEGF Drug Product and Services
2.5.4 Allergan Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Allergan Recent Developments/Updates
2.6 Bayer AG
2.6.1 Bayer AG Details
2.6.2 Bayer AG Major Business
2.6.3 Bayer AG Anti-VEGF Drug Product and Services
2.6.4 Bayer AG Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Bayer AG Recent Developments/Updates
2.7 Regeneron Pharmaceuticals Inc.
2.7.1 Regeneron Pharmaceuticals Inc. Details
2.7.2 Regeneron Pharmaceuticals Inc. Major Business
2.7.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product and Services
2.7.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Regeneron Pharmaceuticals Inc. Recent Developments/Updates
2.8 Viatris Inc
2.8.1 Viatris Inc Details
2.8.2 Viatris Inc Major Business
2.8.3 Viatris Inc Anti-VEGF Drug Product and Services
2.8.4 Viatris Inc Anti-VEGF Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Viatris Inc Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: ANTI-VEGF DRUG BY MANUFACTURER
3.1 Global Anti-VEGF Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Anti-VEGF Drug Revenue by Manufacturer (2018-2023)
3.3 Global Anti-VEGF Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Anti-VEGF Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Anti-VEGF Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Anti-VEGF Drug Manufacturer Market Share in 2022
3.5 Anti-VEGF Drug Market: Overall Company Footprint Analysis
3.5.1 Anti-VEGF Drug Market: Region Footprint
3.5.2 Anti-VEGF Drug Market: Company Product Type Footprint
3.5.3 Anti-VEGF Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Anti-VEGF Drug Market Size by Region
4.1.1 Global Anti-VEGF Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Anti-VEGF Drug Consumption Value by Region (2018-2029)
4.1.3 Global Anti-VEGF Drug Average Price by Region (2018-2029)
4.2 North America Anti-VEGF Drug Consumption Value (2018-2029)
4.3 Europe Anti-VEGF Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Anti-VEGF Drug Consumption Value (2018-2029)
4.5 South America Anti-VEGF Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Anti-VEGF Drug Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Anti-VEGF Drug Sales Quantity by Type (2018-2029)
5.2 Global Anti-VEGF Drug Consumption Value by Type (2018-2029)
5.3 Global Anti-VEGF Drug Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Anti-VEGF Drug Sales Quantity by Application (2018-2029)
6.2 Global Anti-VEGF Drug Consumption Value by Application (2018-2029)
6.3 Global Anti-VEGF Drug Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Anti-VEGF Drug Sales Quantity by Type (2018-2029)
7.2 North America Anti-VEGF Drug Sales Quantity by Application (2018-2029)
7.3 North America Anti-VEGF Drug Market Size by Country
7.3.1 North America Anti-VEGF Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Anti-VEGF Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Anti-VEGF Drug Sales Quantity by Type (2018-2029)
8.2 Europe Anti-VEGF Drug Sales Quantity by Application (2018-2029)
8.3 Europe Anti-VEGF Drug Market Size by Country
8.3.1 Europe Anti-VEGF Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Anti-VEGF Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Anti-VEGF Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Anti-VEGF Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Anti-VEGF Drug Market Size by Region
9.3.1 Asia-Pacific Anti-VEGF Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Anti-VEGF Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Anti-VEGF Drug Sales Quantity by Type (2018-2029)
10.2 South America Anti-VEGF Drug Sales Quantity by Application (2018-2029)
10.3 South America Anti-VEGF Drug Market Size by Country
10.3.1 South America Anti-VEGF Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Anti-VEGF Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Anti-VEGF Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Anti-VEGF Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Anti-VEGF Drug Market Size by Country
11.3.1 Middle East & Africa Anti-VEGF Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Anti-VEGF Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Anti-VEGF Drug Market Drivers
12.2 Anti-VEGF Drug Market Restraints
12.3 Anti-VEGF Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Anti-VEGF Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Anti-VEGF Drug
13.3 Anti-VEGF Drug Production Process
13.4 Anti-VEGF Drug Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Anti-VEGF Drug Typical Distributors
14.3 Anti-VEGF Drug Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Anti-VEGF Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Anti-VEGF Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 4. F. Hoffmann-La Roche Ltd Major Business
Table 5. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product and Services
Table 6. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 8. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 9. Amgen Inc Major Business
Table 10. Amgen Inc Anti-VEGF Drug Product and Services
Table 11. Amgen Inc Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Amgen Inc Recent Developments/Updates
Table 13. Pfizer, Inc Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer, Inc Major Business
Table 15. Pfizer, Inc Anti-VEGF Drug Product and Services
Table 16. Pfizer, Inc Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer, Inc Recent Developments/Updates
Table 18. Xbrane Biopharma AB Basic Information, Manufacturing Base and Competitors
Table 19. Xbrane Biopharma AB Major Business
Table 20. Xbrane Biopharma AB Anti-VEGF Drug Product and Services
Table 21. Xbrane Biopharma AB Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Xbrane Biopharma AB Recent Developments/Updates
Table 23. Allergan Basic Information, Manufacturing Base and Competitors
Table 24. Allergan Major Business
Table 25. Allergan Anti-VEGF Drug Product and Services
Table 26. Allergan Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Allergan Recent Developments/Updates
Table 28. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 29. Bayer AG Major Business
Table 30. Bayer AG Anti-VEGF Drug Product and Services
Table 31. Bayer AG Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Bayer AG Recent Developments/Updates
Table 33. Regeneron Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 34. Regeneron Pharmaceuticals Inc. Major Business
Table 35. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product and Services
Table 36. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Regeneron Pharmaceuticals Inc. Recent Developments/Updates
Table 38. Viatris Inc Basic Information, Manufacturing Base and Competitors
Table 39. Viatris Inc Major Business
Table 40. Viatris Inc Anti-VEGF Drug Product and Services
Table 41. Viatris Inc Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Viatris Inc Recent Developments/Updates
Table 43. Global Anti-VEGF Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 44. Global Anti-VEGF Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 45. Global Anti-VEGF Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 46. Market Position of Manufacturers in Anti-VEGF Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 47. Head Office and Anti-VEGF Drug Production Site of Key Manufacturer
Table 48. Anti-VEGF Drug Market: Company Product Type Footprint
Table 49. Anti-VEGF Drug Market: Company Product Application Footprint
Table 50. Anti-VEGF Drug New Market Entrants and Barriers to Market Entry
Table 51. Anti-VEGF Drug Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Anti-VEGF Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 53. Global Anti-VEGF Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 54. Global Anti-VEGF Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 55. Global Anti-VEGF Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 56. Global Anti-VEGF Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 57. Global Anti-VEGF Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 58. Global Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 59. Global Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 60. Global Anti-VEGF Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 61. Global Anti-VEGF Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 62. Global Anti-VEGF Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 63. Global Anti-VEGF Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 64. Global Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 65. Global Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 66. Global Anti-VEGF Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 67. Global Anti-VEGF Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 68. Global Anti-VEGF Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 69. Global Anti-VEGF Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 70. North America Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 71. North America Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 72. North America Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 73. North America Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 74. North America Anti-VEGF Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 75. North America Anti-VEGF Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 76. North America Anti-VEGF Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 77. North America Anti-VEGF Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 78. Europe Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Europe Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Europe Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 81. Europe Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 82. Europe Anti-VEGF Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 83. Europe Anti-VEGF Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 84. Europe Anti-VEGF Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Anti-VEGF Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 87. Asia-Pacific Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 88. Asia-Pacific Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 89. Asia-Pacific Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 90. Asia-Pacific Anti-VEGF Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 91. Asia-Pacific Anti-VEGF Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 92. Asia-Pacific Anti-VEGF Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 93. Asia-Pacific Anti-VEGF Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 94. South America Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 95. South America Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 96. South America Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 97. South America Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 98. South America Anti-VEGF Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 99. South America Anti-VEGF Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 100. South America Anti-VEGF Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 101. South America Anti-VEGF Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 102. Middle East & Africa Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 103. Middle East & Africa Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 104. Middle East & Africa Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 105. Middle East & Africa Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 106. Middle East & Africa Anti-VEGF Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 107. Middle East & Africa Anti-VEGF Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 108. Middle East & Africa Anti-VEGF Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 109. Middle East & Africa Anti-VEGF Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 110. Anti-VEGF Drug Raw Material
Table 111. Key Manufacturers of Anti-VEGF Drug Raw Materials
Table 112. Anti-VEGF Drug Typical Distributors
Table 113. Anti-VEGF Drug Typical Customers
Table 1. Global Anti-VEGF Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Anti-VEGF Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 4. F. Hoffmann-La Roche Ltd Major Business
Table 5. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product and Services
Table 6. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. F. Hoffmann-La Roche Ltd Recent Developments/Updates
Table 8. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 9. Amgen Inc Major Business
Table 10. Amgen Inc Anti-VEGF Drug Product and Services
Table 11. Amgen Inc Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Amgen Inc Recent Developments/Updates
Table 13. Pfizer, Inc Basic Information, Manufacturing Base and Competitors
Table 14. Pfizer, Inc Major Business
Table 15. Pfizer, Inc Anti-VEGF Drug Product and Services
Table 16. Pfizer, Inc Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Pfizer, Inc Recent Developments/Updates
Table 18. Xbrane Biopharma AB Basic Information, Manufacturing Base and Competitors
Table 19. Xbrane Biopharma AB Major Business
Table 20. Xbrane Biopharma AB Anti-VEGF Drug Product and Services
Table 21. Xbrane Biopharma AB Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Xbrane Biopharma AB Recent Developments/Updates
Table 23. Allergan Basic Information, Manufacturing Base and Competitors
Table 24. Allergan Major Business
Table 25. Allergan Anti-VEGF Drug Product and Services
Table 26. Allergan Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Allergan Recent Developments/Updates
Table 28. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 29. Bayer AG Major Business
Table 30. Bayer AG Anti-VEGF Drug Product and Services
Table 31. Bayer AG Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Bayer AG Recent Developments/Updates
Table 33. Regeneron Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 34. Regeneron Pharmaceuticals Inc. Major Business
Table 35. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product and Services
Table 36. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Regeneron Pharmaceuticals Inc. Recent Developments/Updates
Table 38. Viatris Inc Basic Information, Manufacturing Base and Competitors
Table 39. Viatris Inc Major Business
Table 40. Viatris Inc Anti-VEGF Drug Product and Services
Table 41. Viatris Inc Anti-VEGF Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Viatris Inc Recent Developments/Updates
Table 43. Global Anti-VEGF Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 44. Global Anti-VEGF Drug Revenue by Manufacturer (2018-2023) & (USD Million)
Table 45. Global Anti-VEGF Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 46. Market Position of Manufacturers in Anti-VEGF Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 47. Head Office and Anti-VEGF Drug Production Site of Key Manufacturer
Table 48. Anti-VEGF Drug Market: Company Product Type Footprint
Table 49. Anti-VEGF Drug Market: Company Product Application Footprint
Table 50. Anti-VEGF Drug New Market Entrants and Barriers to Market Entry
Table 51. Anti-VEGF Drug Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Anti-VEGF Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 53. Global Anti-VEGF Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 54. Global Anti-VEGF Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 55. Global Anti-VEGF Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 56. Global Anti-VEGF Drug Average Price by Region (2018-2023) & (US$/Unit)
Table 57. Global Anti-VEGF Drug Average Price by Region (2024-2029) & (US$/Unit)
Table 58. Global Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 59. Global Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 60. Global Anti-VEGF Drug Consumption Value by Type (2018-2023) & (USD Million)
Table 61. Global Anti-VEGF Drug Consumption Value by Type (2024-2029) & (USD Million)
Table 62. Global Anti-VEGF Drug Average Price by Type (2018-2023) & (US$/Unit)
Table 63. Global Anti-VEGF Drug Average Price by Type (2024-2029) & (US$/Unit)
Table 64. Global Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 65. Global Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 66. Global Anti-VEGF Drug Consumption Value by Application (2018-2023) & (USD Million)
Table 67. Global Anti-VEGF Drug Consumption Value by Application (2024-2029) & (USD Million)
Table 68. Global Anti-VEGF Drug Average Price by Application (2018-2023) & (US$/Unit)
Table 69. Global Anti-VEGF Drug Average Price by Application (2024-2029) & (US$/Unit)
Table 70. North America Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 71. North America Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 72. North America Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 73. North America Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 74. North America Anti-VEGF Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 75. North America Anti-VEGF Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 76. North America Anti-VEGF Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 77. North America Anti-VEGF Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 78. Europe Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 79. Europe Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 80. Europe Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 81. Europe Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 82. Europe Anti-VEGF Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 83. Europe Anti-VEGF Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 84. Europe Anti-VEGF Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Anti-VEGF Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 87. Asia-Pacific Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 88. Asia-Pacific Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 89. Asia-Pacific Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 90. Asia-Pacific Anti-VEGF Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 91. Asia-Pacific Anti-VEGF Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 92. Asia-Pacific Anti-VEGF Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 93. Asia-Pacific Anti-VEGF Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 94. South America Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 95. South America Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 96. South America Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 97. South America Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 98. South America Anti-VEGF Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 99. South America Anti-VEGF Drug Sales Quantity by Country (2024-2029) & (K Units)
Table 100. South America Anti-VEGF Drug Consumption Value by Country (2018-2023) & (USD Million)
Table 101. South America Anti-VEGF Drug Consumption Value by Country (2024-2029) & (USD Million)
Table 102. Middle East & Africa Anti-VEGF Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 103. Middle East & Africa Anti-VEGF Drug Sales Quantity by Type (2024-2029) & (K Units)
Table 104. Middle East & Africa Anti-VEGF Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 105. Middle East & Africa Anti-VEGF Drug Sales Quantity by Application (2024-2029) & (K Units)
Table 106. Middle East & Africa Anti-VEGF Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 107. Middle East & Africa Anti-VEGF Drug Sales Quantity by Region (2024-2029) & (K Units)
Table 108. Middle East & Africa Anti-VEGF Drug Consumption Value by Region (2018-2023) & (USD Million)
Table 109. Middle East & Africa Anti-VEGF Drug Consumption Value by Region (2024-2029) & (USD Million)
Table 110. Anti-VEGF Drug Raw Material
Table 111. Key Manufacturers of Anti-VEGF Drug Raw Materials
Table 112. Anti-VEGF Drug Typical Distributors
Table 113. Anti-VEGF Drug Typical Customers
LIST OF FIGURES
Figure 1. Anti-VEGF Drug Picture
Figure 2. Global Anti-VEGF Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Anti-VEGF Drug Consumption Value Market Share by Type in 2022
Figure 4. Avastin Examples
Figure 5. Lucentis Examples
Figure 6. Eylea Examples
Figure 7. Global Anti-VEGF Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Anti-VEGF Drug Consumption Value Market Share by Application in 2022
Figure 9. Age-related Macular Degeneration Examples
Figure 10. Macular Edema Following Retinal Vein Occlusion Examples
Figure 11. Diabetic Macular Edema Examples
Figure 12. Diabetic Retinopathy Examples
Figure 13. Global Anti-VEGF Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Anti-VEGF Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Anti-VEGF Drug Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Anti-VEGF Drug Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Anti-VEGF Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Anti-VEGF Drug Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Anti-VEGF Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Anti-VEGF Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Anti-VEGF Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Anti-VEGF Drug Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Anti-VEGF Drug Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Anti-VEGF Drug Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Anti-VEGF Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Anti-VEGF Drug Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Anti-VEGF Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Anti-VEGF Drug Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Anti-VEGF Drug Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Anti-VEGF Drug Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Anti-VEGF Drug Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Anti-VEGF Drug Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Anti-VEGF Drug Consumption Value Market Share by Region (2018-2029)
Figure 55. China Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Anti-VEGF Drug Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Anti-VEGF Drug Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Anti-VEGF Drug Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Anti-VEGF Drug Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Anti-VEGF Drug Market Drivers
Figure 76. Anti-VEGF Drug Market Restraints
Figure 77. Anti-VEGF Drug Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Anti-VEGF Drug in 2022
Figure 80. Manufacturing Process Analysis of Anti-VEGF Drug
Figure 81. Anti-VEGF Drug Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Figure 1. Anti-VEGF Drug Picture
Figure 2. Global Anti-VEGF Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Anti-VEGF Drug Consumption Value Market Share by Type in 2022
Figure 4. Avastin Examples
Figure 5. Lucentis Examples
Figure 6. Eylea Examples
Figure 7. Global Anti-VEGF Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Anti-VEGF Drug Consumption Value Market Share by Application in 2022
Figure 9. Age-related Macular Degeneration Examples
Figure 10. Macular Edema Following Retinal Vein Occlusion Examples
Figure 11. Diabetic Macular Edema Examples
Figure 12. Diabetic Retinopathy Examples
Figure 13. Global Anti-VEGF Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 14. Global Anti-VEGF Drug Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 15. Global Anti-VEGF Drug Sales Quantity (2018-2029) & (K Units)
Figure 16. Global Anti-VEGF Drug Average Price (2018-2029) & (US$/Unit)
Figure 17. Global Anti-VEGF Drug Sales Quantity Market Share by Manufacturer in 2022
Figure 18. Global Anti-VEGF Drug Consumption Value Market Share by Manufacturer in 2022
Figure 19. Producer Shipments of Anti-VEGF Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 20. Top 3 Anti-VEGF Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Top 6 Anti-VEGF Drug Manufacturer (Consumption Value) Market Share in 2022
Figure 22. Global Anti-VEGF Drug Sales Quantity Market Share by Region (2018-2029)
Figure 23. Global Anti-VEGF Drug Consumption Value Market Share by Region (2018-2029)
Figure 24. North America Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East & Africa Anti-VEGF Drug Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 30. Global Anti-VEGF Drug Consumption Value Market Share by Type (2018-2029)
Figure 31. Global Anti-VEGF Drug Average Price by Type (2018-2029) & (US$/Unit)
Figure 32. Global Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 33. Global Anti-VEGF Drug Consumption Value Market Share by Application (2018-2029)
Figure 34. Global Anti-VEGF Drug Average Price by Application (2018-2029) & (US$/Unit)
Figure 35. North America Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 36. North America Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 37. North America Anti-VEGF Drug Sales Quantity Market Share by Country (2018-2029)
Figure 38. North America Anti-VEGF Drug Consumption Value Market Share by Country (2018-2029)
Figure 39. United States Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Canada Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Mexico Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Europe Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 43. Europe Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 44. Europe Anti-VEGF Drug Sales Quantity Market Share by Country (2018-2029)
Figure 45. Europe Anti-VEGF Drug Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. France Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. United Kingdom Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Russia Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Italy Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Anti-VEGF Drug Sales Quantity Market Share by Region (2018-2029)
Figure 54. Asia-Pacific Anti-VEGF Drug Consumption Value Market Share by Region (2018-2029)
Figure 55. China Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Japan Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Korea Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. India Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Southeast Asia Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Australia Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. South America Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 62. South America Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 63. South America Anti-VEGF Drug Sales Quantity Market Share by Country (2018-2029)
Figure 64. South America Anti-VEGF Drug Consumption Value Market Share by Country (2018-2029)
Figure 65. Brazil Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Argentina Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 67. Middle East & Africa Anti-VEGF Drug Sales Quantity Market Share by Type (2018-2029)
Figure 68. Middle East & Africa Anti-VEGF Drug Sales Quantity Market Share by Application (2018-2029)
Figure 69. Middle East & Africa Anti-VEGF Drug Sales Quantity Market Share by Region (2018-2029)
Figure 70. Middle East & Africa Anti-VEGF Drug Consumption Value Market Share by Region (2018-2029)
Figure 71. Turkey Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Egypt Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Saudi Arabia Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. South Africa Anti-VEGF Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Anti-VEGF Drug Market Drivers
Figure 76. Anti-VEGF Drug Market Restraints
Figure 77. Anti-VEGF Drug Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Anti-VEGF Drug in 2022
Figure 80. Manufacturing Process Analysis of Anti-VEGF Drug
Figure 81. Anti-VEGF Drug Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
